1. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
- Author
-
Fabian Trillsch, Sven Mahner, Beyhan Ataseven, Rebecca Asher, Nanda Aryal, Coraline Dubot, Andrew Clamp, Richard T. Penson, Amit Oza, Amnon Amit, Tomasz Huzarski, Antonio Casado, Giovanni Scambia, Michael Friedlander, Nicoletta Colombo, Keiichi Fujiwara, Gabe S. Sonke, Hannelore Denys, Elizabeth S. Lowe, Chee K. Lee, Eric Pujade-Lauraine, Trillsch, F, Mahner, S, Ataseven, B, Asher, R, Aryal, N, Dubot, C, Clamp, A, Penson, R, Oza, A, Amit, A, Huzarski, T, Casado, A, Scambia, G, Friedlander, M, Colombo, N, Fujiwara, K, Sonke, G, Denys, H, Lowe, E, Lee, C, and Pujade-Lauraine, E
- Subjects
Ovarian Neoplasms ,Age dependency ,Quality of life ,BRCA1 Protein ,Obstetrics and Gynecology ,Carcinoma, Ovarian Epithelial ,Piperazines ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,Olaparib ,PARP inhibitor ,Oncology ,Ovarian cancer ,Child, Preschool ,Mutation ,Humans ,Phthalazines ,Female ,Neoplasm Recurrence, Local ,PARP inhibitors ,Aged - Abstract
Background: Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients appears of special interest. Methods: 295 patients from the SOLO2 trial randomly assigned to olaparib or placebo were categorized according to age-cutoff at 65 years. Efficacy, tolerability, and quality of life (QoL) of olaparib relative to placebo within in each age group was analyzed. Results: Baseline characteristics were similar in patients ≥65 years (N = 62;21.0%) compared to patients
- Published
- 2022